The once-weekly injection and 15.3% mean body weight reduction from STEP-1 trials established Wegovy as the anti-obesity medication clinical benchmark
Supplementing with CoQ10 appears to be well tolerated by individuals and has low toxicity
Because of the urgent need for surgery, laboratory testing for urinary excretion of VMA was not done
15 likewise, lixisenatide was withdrawn from the US market as of January 1, 2023, for commercial reasons, rather than because of any safety or efficacy issues
Perkovic V, Tuttle KR, Rossing P, et al
Pattanayak Monhanty S, Ray JG, Richa, Mukherjee S, Mandal C, Chaudhuri K